Recent Quotes (30 days)

You have no recent quotes
chg | %

Amorfix Life Sciences Ltd.  

(Public, TSE:AMF)   Watch this stock  
Find more results for AMF
0.000 (0.00%)
Apr 17 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.37 - 0.40
52 week 0.20 - 0.45
Open 0.38
Vol / Avg. 20,500.00/50,524.00
Mkt cap 25.12M
P/E     -
Div/yield     -
EPS -0.03
Shares 66.11M
Beta 0.46
Inst. own     -

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1224.25% -4505.05%
Operating margin -1224.25% -4509.73%
EBITD margin - -4408.14%
Return on average assets -463.50% -276.15%
Return on average equity - -752.63%
CDP Score - -


3403 American Drive
+1-416-8476898 (Phone)
+1-416-8476899 (Fax)

Website links


Amorfix Life Sciences Ltd. is a product development company focused on therapeutic antibodies and diagnostics for the diagnosis and treatment of misfolded protein diseases including amyotrophic lateral sclerosis (ALS), cancer and Alzheimer�s disease (AD). The Company is developing diagnostic products with the goal of detecting the presence of aggregated misfolded proteins (AMPs) in tissue, blood or other biofluids. The Company�s technologies are also being used to develop antibody and vaccine therapies that target disease specific epitopes (DSEs) on disease-relevant proteins as an approach to treat these incurable disorders. The Company�s therapeutics is designed to target and neutralize only the misfolded conformation of a given protein. The Company provides Diagnostic Services using its sensitive and specific Diagnostic Kits to Alzheimer's researchers and prion removal equipment manufacturers.

Officers and directors

Neil Cashman M.D. Chairman of the Board, Chief Scientific Officer
Robert Gundel Ph.D. President, Chief Executive Officer, Director
Warren Whitehead Chief Financial Officer
William Copeland Director
Johannes Minho Roth Director
Age: 34
William W. Wyman Director
Age: 75
Hans Peter Black M.D. Independent Director
Age: 60
Aziz Mekouar Independent Director